StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Pares Gains Following FDA Approval
September 19, 2016 10:14 AM
Sarepta Therapeutics (NASDAQ: SRPT) gives ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Momentum Movers
Trader Talk
Next Articles
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM
Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
September 19, 2016 1:37 PM
Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform
September 19, 2016 1:29 PM
Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval
September 19, 2016 1:08 PM
Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
September 19, 2016 11:21 AM
Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer
September 19, 2016 10:40 AM
